{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:43:12Z","timestamp":1783539792191,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This was an analysis of exacerbations in the SUMMIT (Study to Understand Mortality and Morbidity) study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a double-blind, randomized controlled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 \u03bcg), vilanterol (VI; 25 \u03bcg), or the combination of FF\/VI was administered. The primary outcome was all-cause mortality. Exacerbations of COPD were an additional predefined endpoint. A total of 1,368 centers in 43 countries and 16,485 patients with moderate COPD and heightened cardiovascular risk were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Compared with placebo, FF\/VI reduced the rate of moderate and\/or severe exacerbations by 29% (95% confidence interval [CI], 22\u201335; P\u2009&amp;lt;\u20090.001) and the rate of hospitalized exacerbations by 27% (95% CI, 13\u201339; P\u2009&amp;lt;\u20090.001). These relative effects were similar regardless of whether subjects had a history of exacerbation in the year before the study or an FEV1 &amp;lt;60% or \u226560% of predicted. The number needed to treat was not influenced by baseline FEV1 but was influenced by the history of exacerbations. FF\/VI also reduced the rate of exacerbations treated with corticosteroids alone or with corticosteroids and antibiotics but not the rates of those treated with antibiotics alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with moderate chronic airflow obstruction experienced a reduction in exacerbations with FF\/VI compared with placebo, irrespective of a history of exacerbations or baseline FEV1.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 01313676; GSK Study number 113782).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201607-1421oc","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T11:59:57Z","timestamp":1477051197000},"page":"881-888","source":"Crossref","is-referenced-by-count":42,"title":["Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction"],"prefix":"10.1093","volume":"195","author":[{"given":"Fernando J.","family":"Martinez","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, New York"},{"name":"University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Sciences Centre, The University of Manchester and South Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Stockley Park, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Brook","sequence":"additional","affiliation":[{"name":"University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome R.","family":"Celli","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Cowans","sequence":"additional","affiliation":[{"name":"Veramed Ltd., Twickenham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Crim","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dransfield","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kilbride","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Stockley Park, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Yates","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Newby","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Niewoehner","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M. A.","family":"Calverley","sequence":"additional","affiliation":[{"name":"University of Liverpool, Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,1]]},"reference":[{"key":"2026032023382515700_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023382515700_bib2","first-page":"21","article-title":"Exacerbations of COPD","volume":"11","author":"Pavord","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026032023382515700_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1378\/chest.14-1677","article-title":"Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline","volume":"147","author":"Criner","year":"2015","journal-title":"Chest"},{"key":"2026032023382515700_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","article-title":"Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management","volume":"385","author":"Woodruff","year":"2015","journal-title":"Lancet"},{"key":"2026032023382515700_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032023382515700_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2026032023382515700_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1183\/09031936.00087312","article-title":"The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol","volume":"41","author":"Vestbo","year":"2013","journal-title":"Eur Respir J"},{"key":"2026032023382515700_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023382515700_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1368-5031.2005.00664.x","article-title":"Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis","volume":"59","author":"Halpin","year":"2005","journal-title":"Int J Clin Pract"},{"key":"2026032023382515700_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1183\/09031936.00194610","article-title":"Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study","volume":"39","author":"Jenkins","year":"2012","journal-title":"Eur Respir J"},{"key":"2026032023382515700_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1378\/chest.11-0281","article-title":"Influence of season on exacerbation characteristics in patients with COPD","volume":"141","author":"Donaldson","year":"2012","journal-title":"Chest"},{"key":"2026032023382515700_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1378\/chest.12-1277","article-title":"Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial","volume":"143","author":"Rabe","year":"2013","journal-title":"Chest"},{"issue":"4","key":"2026032023382515700_bib13","first-page":"CD003794","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023382515700_bib14","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"9","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023382515700_bib15","first-page":"CD006826","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease","volume":"8","author":"Nannini","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023382515700_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","article-title":"Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study","volume":"10","author":"Jenkins","year":"2009","journal-title":"Respir Res"},{"key":"2026032023382515700_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"2026032023382515700_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"key":"2026032023382515700_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"2026032023382515700_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023382515700_bib21","doi-asserted-by":"crossref","first-page":"e47305","DOI":"10.1371\/journal.pone.0047305","article-title":"The lung microbiome in moderate and severe chronic obstructive pulmonary disease","volume":"7","author":"Pragman","year":"2012","journal-title":"PLoS One"},{"key":"2026032023382515700_bib22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1183\/13993003.01406-2015","article-title":"Lung microbiome dynamics in COPD exacerbations","volume":"47","author":"Wang","year":"2016","journal-title":"Eur Respir J"},{"key":"2026032023382515700_bib23","first-page":"A5383","article-title":"Glucocorticoid-augmented efferocytosis impairs host defense by alveolar macrophages of human smokers by reducing specific microRNAs","volume":"191","author":"Freeman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023382515700_bib24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.09-2992","article-title":"Reported pneumonia in patients with COPD: findings from the INSPIRE study","volume":"139","author":"Calverley","year":"2011","journal-title":"Chest"},{"key":"2026032023382515700_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026032023382515700_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1753465816630208","article-title":"Inhaled corticosteroids and the increased risk of pneumonia: what\u2019s new? A 2015 updated review","volume":"10","author":"Iannella","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"2026032023382515700_bib27","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023382515700_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"2026032023382515700_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"2026032023382515700_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1513\/AnnalsATS.201408-359OC","article-title":"Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease","volume":"12","author":"Huerta","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026032023382515700_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1440-1843.2010.01908.x","article-title":"A hypothesis to phenotype COPD exacerbations by aetiology","volume":"16","author":"MacDonald","year":"2011","journal-title":"Respirology"},{"key":"2026032023382515700_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/resp.12197","article-title":"Exacerbation phenotyping in chronic obstructive pulmonary disease","volume":"18","author":"MacDonald","year":"2013","journal-title":"Respirology"},{"key":"2026032023382515700_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S2213-2600(15)00242-8","article-title":"Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal","volume":"3","author":"Lopez-Campos","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026032023382515700_bib34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/thoraxjnl-2012-202709","article-title":"Number needed to treat in COPD: exacerbations versus pneumonias","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"key":"2026032023382515700_bib35","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/7\/881\/67162397\/ajrccm_195_7_881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/7\/881\/67162397\/ajrccm_195_7_881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:38:58Z","timestamp":1774064338000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/195\/7\/881\/8500090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,1]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201607-1421oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4]]},"published":{"date-parts":[[2017,4,1]]}}}